CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Biopharma and Cigalah, two of the largest and most ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA ® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
The FDA approved nogapendekin alfa inbakicept (Anktiva) for bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC), the agency announced Monday. A first-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results